Your browser doesn't support javascript.
loading
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
Pascual, J; Attard, G; Bidard, F-C; Curigliano, G; De Mattos-Arruda, L; Diehn, M; Italiano, A; Lindberg, J; Merker, J D; Montagut, C; Normanno, N; Pantel, K; Pentheroudakis, G; Popat, S; Reis-Filho, J S; Tie, J; Seoane, J; Tarazona, N; Yoshino, T; Turner, N C.
Afiliación
  • Pascual J; Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Malaga, Spain.
  • Attard G; Urological Cancer Research, University College London, London, UK.
  • Bidard FC; Department of Medical Oncology, Institut Curie, Paris, France; University of Versailles Saint-Quentin-en-Yvelines (UVSQ)/Paris-Saclay University, Saint Cloud, France.
  • Curigliano G; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy; Division of Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy.
  • De Mattos-Arruda L; IrsiCaixa, Hospital Universitari Trias i Pujol, Badalona, Spain; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Diehn M; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, USA.
  • Italiano A; Early Phase Trials and Sarcoma Units, Institut Bergonie, Bordeaux, France; DITEP, Gustave Roussy, Villejuif, France; Faculty of Medicine, University of Bordeaux, Bordeaux, France.
  • Lindberg J; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden.
  • Merker JD; Departments of Pathology and Laboratory Medicine & Genetics, UNC School of Medicine, Chapel Hill, USA.
  • Montagut C; Medical Oncology Department, Hospital del Mar-IMIM, CIBERONC, Universitat Pompeu Fabra, Barcelona, Spain.
  • Normanno N; Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, 'Fondazione G. Pascale' - IRCCS, Naples, Italy.
  • Pantel K; Institute for Tumour Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
  • Pentheroudakis G; Scientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland.
  • Popat S; Royal Marsden Hospital, London, UK; Institute of Cancer Research, London, UK.
  • Reis-Filho JS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Tie J; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Division of Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
  • Seoane J; Preclinical and Translational Research Programme, Vall d'Hebron Institute of Oncology (VHIO), ICREA, CIBERONC, Barcelona, Spain; Medical School, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Tarazona N; Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; Instituto de Salud Carlos III, CIBERONC, Madrid, Spain.
  • Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Turner NC; Royal Marsden Hospital, London, UK; Institute of Cancer Research, London, UK. Electronic address: education@esmo.org.
Ann Oncol ; 33(8): 750-768, 2022 08.
Article en En | MEDLINE | ID: mdl-35809752

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ADN Tumoral Circulante Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ADN Tumoral Circulante Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido